

# Cancer Biomarkers Market to Targets \$26.97 Billion by 2027

PORTLAND, CT, UNITED STATES, September 12, 2024 /EINPresswire.com/ -- According to the report, the global [cancer biomarkers industry](#) was estimated at \$10.94 billion in 2019, and is expected to hit \$26.97 billion by 2027, registering a CAGR of 11.8% from 2020 to 2027.

Prevalence of various types of cancers such as breast, prostate, and lung cancer, development of biological & targeted drug therapies, and reliability of cancer biomarkers fuel the growth of the global cancer biomarkers market. On the other hand, high cost of drug development, threat of failure associated with cancer treatment, and unregulated government regulations & reimbursement policies impede the growth to some extent. However, high-end technological advancements are expected to create multiple opportunities in the industry.

## Key Takeaways:

The cancer biomarkers market is experiencing significant growth due to advancements in genomic and proteomic technologies, increasing prevalence of cancer, and the need for personalized medicine.

Biomarkers play a crucial role in cancer diagnosis, prognosis, treatment selection, and monitoring of therapeutic response.

The market is driven by the increasing demand for non-invasive and early detection methods for cancer, as well as the development of targeted therapies.

Liquid biopsy-based biomarkers are gaining traction as they offer minimally invasive testing and can provide real-time information about tumor progression and treatment response.

Request Sample Copy of the Report: <https://www.alliedmarketresearch.com/request-sample/1443>

## Market Segmentation:

### Biomarker Type:

Genetic Biomarkers (mutations, gene expression)

Proteomic Biomarkers (proteins, circulating tumor cells)  
Epigenetic Biomarkers (DNA methylation, histone modifications)

Cancer Type:

Breast Cancer  
Lung Cancer  
Prostate Cancer  
Colorectal Cancer  
Melanoma  
Leukemia  
Others

Application:

Diagnosis  
Prognosis  
Treatment Selection  
Monitoring and Recurrence Detection

Technology:

Immunoassays  
Next-generation Sequencing (NGS)  
Polymerase Chain Reaction (PCR)  
Mass Spectrometry  
In Situ Hybridization (ISH)

End-user:

Hospitals  
Diagnostic Laboratories  
Research Institutions  
Pharmaceutical Companies

Region:

North America  
Europe  
Asia Pacific  
Latin America  
Middle East and Africa

These segmentation factors allow for a more targeted analysis of the cancer biomarkers market

and help in understanding specific market dynamics and trends for each segment.

Request for Customization –

<https://www.alliedmarketresearch.com/request-for-customization/1443>

Regional Growth Dynamics:

North America and Europe are the most lucrative markets due to increase in prevalence of various cancer cases, growth in awareness toward cancer, higher cancer biomarker testing, well-established reimbursement policies, and high disposable income. The North America cancer biomarker market generated \$3,988.02 million revenue in 2019, and is estimated to garner an approximate revenue of \$8,733.26 million by 2027, at an estimated CAGR of 10.1%.

Buy this Premium Research Report: <https://www.alliedmarketresearch.com/purchase-enquiry/1443>

Competitive Landscape:

F. Hoffmann-La Roche Ltd.  
Thermo Fisher Scientific, Inc.  
Illumina, Inc.  
QIAGEN N.V.  
Abbott Laboratories  
Bio-Rad Laboratories, Inc.  
Agilent Technologies, Inc.  
Siemens Healthineers AG  
Merck KGaA  
Myriad Genetics, Inc.

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa  
Allied Market Research  
+1 800-792-5285  
[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/742818401>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.